



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>A61K 38/02, C07K 14/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/29087</b> <b>(43) International Publication Date:</b> 26 September 1996 (26.09.96)
<b>(21) International Application Number:</b> PCT/US96/03308 <b>(22) International Filing Date:</b> 20 March 1996 (20.03.96) <b>(30) Priority Data:</b> 08/407,899 21 March 1995 (21.03.95) US <b>(71) Applicant:</b> CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY [US/US]; One Bruce Street, Newark, NJ 07103-2763 (US). <b>(72) Inventors:</b> BEHR, Thomas, M.; 43 La France Avenue, Bloomfield, NJ 07003-5631 (US). GOLDENBERG, David, M.; 30 Pleasant Valley Road, Mendham, NJ 07945 (US). <b>(74) Agents:</b> SAXE, Bernhard, D. et al.; Foley & Lardner, Suite 500, 3000 K Street, Washington, DC 20007-5109 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> METHODS FOR REDUCED RENAL UPTAKE OF ANTIBODY FRAGMENTS  <b>(57) Abstract</b>  Kidney uptake of antibody fragment conjugates in patients is reduced by administration to the patient of one or more compounds selected from the group consisting of D-lysine, poly-D-lysine, or poly-L-lysine, or pharmaceutically acceptable salts or carboxyl derivatives thereof.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## METHODS FOR REDUCED RENAL UPTAKE OF ANTIBODY FRAGMENTS

Background of the Invention

This invention relates to a method for reducing renal uptake of monoclonal antibody fragments used for radioimmunodiagnosis (RAID), immunotherapy, and radioimmunotherapy (RAIT). Numerous clinical studies have demonstrated the utility of radiolabeled antibodies for the radioimmunodetection of disease. Antibody fragments, such as Fab', Fab, F(ab')<sub>2</sub>, and F(ab)<sub>2</sub>, have faster targeting kinetics than intact immunoglobulin, and are therefore particularly useful for RAID applications. Other advantages of antibody fragments include a much lower occurrence of human immune responses than is found with intact IgG molecules.

A major drawback to the use of radiolabeled antibody fragments for imaging and therapy is the relatively high uptake and retention of radioactivity in the kidney. This phenomenon can impede diagnostic accuracy, especially in the periaortic and epigastric region, and particularly when intracellularly retained isotopes, such as <sup>111</sup>In or <sup>99m</sup>Tc are used. For example, when <sup>99m</sup>Tc-labeled Fab' fragments are used, renal uptakes of up to 25 % of the injected dose within 24 h have been reported.

The maximum tolerated dose for a kidney is estimated in external beam radiation is 2000 cGy. Above that threshold the risk of radiation nephritis with subsequent scarring of glomeruli, nephrotic syndrome and renal insufficiency rises considerably. It is likely, therefore that in RAIT using antibody fragments labeled with intracellularly retained radiometals (e.g., <sup>90</sup>Y, <sup>168/188</sup>Re, <sup>67</sup>Cu, <sup>177</sup>Lu) the kidney may become the dose-limiting organ.

Renal uptake of peptides and small proteins is thought to occur via glomerular filtration of molecules smaller than 60 kD, with subsequent tubular reabsorption for lysosomal degradation. When radioisotopes such as iodine are liberated by this degradative process they are

retained by binding to ubiquitous intracellular proteins with high affinity for metal ions.

Basic amino acids, such as L-lysine and L-arginine, have been shown to induce functional proteinuria when administered in high dose. Morgenson et al., *Scan. J. Clin. Lab. Invest.* 37:477 (1977). Two previous studies have suggested L-lysine can be effective in decreasing kidney uptake of radiolabeled peptides. Continuous infusion of an amino acid solution containing L-lysine and L-arginine was shown to reduce renal uptake of the <sup>111</sup>In-labeled somatostatin analogue octreotide in humans. Hammond et al. *Brit. J. Cancer* 67:1437 (1993). Repeated intraperitoneal injections of high doses of L-lysine also reduced renal uptake of <sup>111</sup>In-labeled Fab' fragments in BALB/c mice. Pimm et al. *Eur. J. Nucl. Med.* 21:663 (1994).

The requirement for either continuous infusion or repeated injection of amino acids in the methods described by Hammond et al. and by Pimm et al. would cause substantial inconvenience and increased costs in a clinical setting. In addition, the most clinically efficacious dosages of amino acids approach the maximum levels that can be physiologically tolerated before toxicity is observed.

It is apparent, therefore that more convenient methods for reducing renal retention of radiolabeled antibody fragments are greatly to be desired. Methods that are less toxic, and that require fewer and lower dosages are particularly desirable.

#### Summary of the Invention

It is therefore an object of the present invention to provide methods that greatly reduce kidney uptake of antibody fragment conjugates.

In accomplishing the foregoing object of the invention, there has been provided, in accordance with one aspect of the invention, a method of reducing kidney uptake of antibody fragment conjugates in a patient during radioimmunodiagnosis or immunotherapy, comprising

administering to the patient an effective amount of one or more members compounds selected from the group consisting of D-lysine, poly-D-lysine, and poly-L-lysine, or a pharmaceutically acceptable salt or carboxyl derivative thereof. In a preferred embodiment the poly-D-lysine and the poly-L-lysine each have a molecular weight of 15-30 kDa. In another preferred embodiment the antibody fragment conjugate is a radiolabeled conjugate. In another preferred embodiment the radiolabel is an imaging isotope, and the procedure is radioimmunodiagnosis. In another preferred embodiment the conjugate is a cytotoxic agent and the procedure is immunotherapy.

In accordance with another aspect of the invention there have been provided methods wherein D-lysine, poly-D-lysine, or poly-L-lysine is administered to said patient.

In accordance with yet another aspect of the invention, there has been provided a method wherein a mixture of at least two of compounds selected from D-lysine, poly-D-lysine, and poly-L-lysine is administered to said patient.

There has been provided, in accordance with still another aspect of the invention, a method wherein a compound selected from the group consisting of D-lysine, poly-D-lysine, and poly-L-lysine is parenterally administered to a patient in a physiologically acceptable aqueous solution. In a preferred embodiment the solution is administered by continuous infusion. In another preferred embodiment the solution is administered by means of at least one injection of a bolus of said solution.

In accordance with yet another aspect of the invention, there has been provided a method wherein a compound selected from the group consisting of D-lysine, poly-D-lysine, and poly-L-lysine is orally administered to a patient.

Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

#### Brief Description of the Drawings

Figure 1 shows the kidney uptake kinetics and organ distribution of  $^{99m}\text{Tc}$ -Fab' NP-4 in BALB/c mice.

Figure 2 shows the dose-effect relationship between L-lysine hydrochloride, administered intraperitoneally in hourly intervals, and the kidney uptake of  $^{99m}\text{Tc}$ -labeled Fab' fragments of the anti-CEA MAb NP-4 in BALB/c mice, after 4h (upper graph) or 24h (lower graph) post-injection.

Figure 3 shows the effect of L-lysine treatment on kidney uptake of directly  $^{188}\text{Re}$ -labeled anti-CSAp Mu-9 Fab' in nude mice bearing GW39 colonic cancer xenografts.

Figure 4 shows the effect of L-lysine treatment on kidney uptake of  $^{111}\text{In}$  (upper graph) and  $^{88}\text{Y}$ -Bz-DTPA (lower graph) labeled Fab' MN-14 in GW39 bearing nude mice colonic cancer xenografts.

Figure 5 shows the effect of the frequency of the intraperitoneal administration of lysine, poly-L-lysine and mixtures thereof on the kidney uptake of  $^{99m}\text{Tc}$ -Fab' NP-4.

Figure 6 shows a time course of the effect of L-lysine on reduction of kidney uptake of  $^{88}\text{Y}$  and  $^{111}\text{In}$ -labeled F(ab)<sub>2</sub> fragments of the anti-CEA antibody MN-14.

Figure 7 shows the effects of a commercially available amino acid solution (containing 1.75 g of L-lysine) on kidney uptake in five patients undergoing RAID studies with  $^{99m}\text{Tc}$ -Fab' fragments of the anti-CEA MAbs F023C5 and NP-4. Control patients were given an equal volume of saline.

Detailed Description

The present invention provides a means of achieving a significant reduction of the kidney retention of antibody fragment conjugates during RAID or immunotherapy. The reduction is achieved by administration to patients of solutions containing D-lysine alone, or lysine plus poly-lysine, prior to the RAID or RAIT procedure. Additional doses of the solutions may also be administered after delivery of the radiolabeled antibody.

As used herein, a "significant" reduction in renal uptake and retention of radioisotope during a RAID procedure means a reduction at the time of imaging by at least approximately a factor of 2, more preferably a factor of approximately 3 or greater, relative to a procedure in which the solutions of the invention are not used. Another measure of "significant" reduction in renal uptake and retention of radioisotope is the ability to clearly detect and image a tumor or infectious lesion that is otherwise obscured by high background radiation in the vicinity of the kidney when the solutions of the invention are not used, especially at short imaging times of, e.g. 1-5 hours. In general, the reduction will be most pronounced at short imaging times, affording real advantages to the clinician.

Similarly, a "significant" reduction in renal uptake and retention of radioisotope during immunotherapy means that a dose of antibody fragment conjugate can be used that is at least approximately 2-3 fold times higher than could otherwise be used without risk of kidney damage.

Some radioisotopes that are preferred for RAID applications, such as technetium-99m, have short half-lives (for example,  $t_{1/2}$  of Tc-99m is six hours). This means that rapid targeting of an antibody with one of these isotopes is desirable. Antibody fragments such as  $F(ab')$ , and  $F(ab)_2$ , and especially Fab, Fab', show more rapid targeting kinetics than whole immunoglobulin, and are also associated with a much lower incidence of human

anti-murine antibody (HAMA) immune responses. Therefore, they are preferred for RAID applications using isotopes such as Tc-99m.

For immunotherapy applications, whole antibody or  
5 bivalent antibody fragments such as  $F(ab')_2$  and  $F(ab)_2$ , are often preferred due to their higher binding constants. Whole antibodies are usually effectively cleared through the liver, and do not pose a significant problem of kidney toxicity.  $F(ab')_2$  and  $F(ab)_2$  antibody fragments,  
10 however, though too large to be effectively filtered through the glomerular basal membrane, nevertheless can still cause significant problems with kidney retention and toxicity during immunotherapy or RAIT.

Previous workers have shown that a continuously  
15 infused solution of basic L-amino acids reduced kidney retention of radioactivity in patients being treated with a radiolabeled peptide. See *Hammond et al., supra*. It has also been shown that repeated high doses of L-lysine can reduce the level of retention of radioactivity in the  
20 kidneys of mice treated with radiolabeled antibody fragments. See *Mimm et al., supra*.

In the methods described in the prior work, however, the maximum achievable reduction in kidney retention is limited by the dosage of basic amino acids that can be  
25 tolerated without causing toxicity. This toxicity is presumably due to effects of the naturally-occurring L-amino acids on amino acid metabolism. Another drawback to the previous work was that the basic amino acids had to be given repeatedly or continuously to achieve the  
30 desired effects.

The present inventors have shown that D-lysine is highly effective in reducing kidney retention of radioactivity in subjects that are treated with radiolabeled antibody fragments. D-Lysine does not occur  
35 naturally in humans or animals and is believed to be metabolically inert, thereby reducing the risk of toxic side-effects associated with the use of L-lysine. Mixtures of D- and L- lysine may also be used.



The present inventors have also shown that low doses of poly-lysine, either alone or in combination with monomeric lysine, produce a desirable reduction in kidney retention of radioactivity. It has also been found that  
5 poly-lysine or poly-lysine/lysine combinations can be administered at lower dosages and less frequently while still retaining the desired reduction of kidney retention of radioactivity. This leads to a lower overall dosage of amino acids to patients, reducing the risks of  
10 toxicity.

The present invention is also useful in immunotherapy applications using antibody fragment conjugates, in which a cytotoxic agent is conjugated to the antibody fragment. Clearance of the fragment through the kidney can lead to  
15 kidney damage caused by accumulation of the cytotoxic agent in the kidney. Administration of monomeric or polymeric lysine reduces the accumulation of the cytotoxic agent, and reduces kidney damage.

#### **A. Selection and Labeling of Antibodies**

The present invention can be used to reduce the kidney retention of antibody fragments that are radiolabeled by any means currently known or that may be known in the future. The term "antibody fragment" as used herein means a molecule which specifically binds to  
20 a complementary antigen and which is derived from a whole immunoglobulin by cleavage, by recombinant methods or by any other process that results in a functional equivalent of a conventional antibody fragment. Examples of  
25 suitable antibody fragments include divalent fragments, e.g.,  $F(ab)_2$ ,  $F(ab')_2$ , monovalent fragments, e.g., Fab, Fab', Fv, single chain recombinant forms of the foregoing, and the like. Antibody fragments may be glycosylated, for example containing carbohydrate  
30 moieties in the antibody variable regions.

The present invention can be used to reduce the kidney retention of antibody fragments that are radiolabeled with any radioisotope useful for RAID or  
35 RAIT. Examples of radioisotopes that are useful for RAID

applications are  $^{99m}\text{Tc}$  and  $^{111}\text{In}$ . Radioisotopes that are useful for RAIT include  $^{32}\text{P}$ ,  $^{90}\text{Y}$ ,  $^{186}\text{Re}$  and  $^{188}\text{Re}$ .

5 The antibody fragment may be radiolabeled by any method known to the art, or by any method that is discovered in the future. For a discussion of methods for radiolabeling antibody fragments see "Cancer Therapy with Monoclonal Antibodies", D.M. Goldenberg ed. (CRC Press, Boca Raton, 1995). The present invention is useful, therefore, for preventing kidney retention of  
10 antibody fragments that are labeled, *inter alia*, by conjugation of a radiometal-binding chelate, by direct radiometal labeling of hinge region sulfhydryl groups, or by radioiodination via the chloramine-T, iodogen, or Bolton-Hunter methods.

15 **B. Administration of Lysine and Poly-lysine for Therapy and Diagnosis.**

Generally, the overall dosage of lysine and/or poly-lysine administered to a patient will be that required to reduce the kidney retention of radiolabeled antibody  
20 fragment to acceptable levels without causing lysine-induced toxicity. The dosage will vary depending upon such factors as the patient's weight, height, general medical condition, and previous medical history. Any physiologically acceptable salt of lysine or poly-lysine  
25 can be used, as can any physiologically acceptable carboxyl derivative of lysine or poly-lysine.

Administration of the monomeric or polymeric lysine or mixture thereof to a patient can be oral, intravenous, intraarterial, intraperitoneal, intramuscular,  
30 subcutaneous, or by perfusion through a regional catheter. Administration may be via single or multiple boluses, or by continuous or discontinuous infusion.

The monomeric or polymeric lysine or mixture thereof may be administered in any pharmaceutically acceptable  
35 solution. A solution is said to be pharmaceutically acceptable if its administration can be tolerated by a recipient patient. Sterile phosphate-buffered saline is one example of a pharmaceutically acceptable carrier.

Other suitable carriers are well-known to those in the art. See, for example, REMINGTON'S PHARMACEUTICAL SCIENCES, 18th Ed. (1990). The concentration of monomeric lysine in the solution is from 3-200 g/l, and that of polymeric lysine is 0.5-100 g/l, although concentrations outside this range may also be used.

An acceptable range for a single dosage of D-lysine administered to a patient is 1-200 g, although a lower or higher dose may be administered. In a preferred embodiment the concentration of lysine in the solution is between approximately 2-35 g/l. In another preferred embodiment, the concentration of lysine in the solution is 15-25 g/l.

Monomeric lysine may need to be administered more than one time to a patient to achieve the desired reduction in kidney uptake. In a preferred embodiment for RAID protocols, monomeric lysine is administered to a patient approximately 30 minutes prior to injection of the labeled antibody fragment, and is then readministered at approximately 1, 2, and 4 hours post-injection. Additional doses of lysine may be given at periodic intervals as deemed necessary to maintain the desired reduction in kidney uptake of radioactivity. In another preferred embodiment suitable for use in both RAID and RAIT protocols, the monomeric lysine is infused at a continuous rate, beginning approximately 30 minutes prior to injection of the labeled antibody. For RAID protocols, administration of lysine can be ended as soon as the imaging process is complete. For RAID protocols, in which much greater amounts of radioactivity are used, administration of lysine is continued until at least 2-3 days after antibody injection.

Equivalent effects on kidney uptake can be achieved with significantly lower doses of poly-lysine than is needed for monomeric lysine. Either D-, D/L- or L-poly-lysine, or any mixture thereof, may be used. The molecular weight range of the poly-lysine may be from 1-60 kDa, although higher molecular weight polymer could

also be used. In a preferred embodiment the poly-lysine has a molecular weight range of approximately 1-4 kDa. In another preferred embodiment the poly-lysine has a molecular weight range of approximately 15-30 kDa.

5 In a preferred embodiment the dosage of poly-lysine administered to a patient in a single bolus is 1-50 mg. Repeated dosage or continuous infusion of poly-lysine is typically not required for RAID applications, but may be needed for prolonged RAIT protocols. The concentration  
10 of poly-lysine in the solution is typically 1-50 g/l, though concentrations outside this range may also be used.

The present inventors have also found that use of mixtures of monomeric and polymeric lysine can reduce  
15 uptake of radioactivity in the kidney to a similar or greater extent than monomeric lysine alone, but with less frequent administrations. Any combination of D- or L-lysine and D-, D/L, or L-poly-lysine may be used to achieve this effect. The molecular weight range of the  
20 poly-lysine used in the mixtures is preferably the same as when poly-lysine is used alone, as described *supra*. The dosage of monomeric lysine administered to a patient in the mixture is typically from 1-200 g, and that of polymeric lysine is typically from 1-50 mg. In both  
25 cases, however, a lower or higher dose may be used. In a preferred embodiment of the invention the dosage of monomeric lysine administered to the patient in a single bolus of the mixture is 2-35g and that of polymeric lysine is 5-25mg. The concentration of monomeric lysine  
30 in the solution is typically between 3-200 g/l, and that of polymeric lysine is 0.5-100 g/l. In a preferred embodiment the concentration of monomeric lysine in the solution is between 2-35 g/l, and that of polymeric lysine is 10-25 g/l.

### 35 C. Determination of effects on kidney uptake of radioactivity

Initial dosage ranges for achieving the desired reduction in kidney uptake of radioactivity can be

determined by using standard animal model systems. Animals are injected with radiolabeled antibody fragments and the level of kidney uptake is compared in animals that are treated with different amounts of lysine or lysine-containing compounds. The results obtained are compared to the results obtained in control animals which receive only the radiolabeled antibody fragments.

A preferred model system is the mouse. For determining the reduction of kidney uptake in non-tumor-bearing subjects the preferred mouse strain is BALB/c mice (Charles River Laboratories, Boston, MA). The preferred strain for determining reductions in tumor-bearing subjects is athymic mice (Harlan, Madison, WI), carrying an engrafted human tumor, such as that produced by subcutaneous injection of the human colon carcinoma cell line GW39 (Primus et al., *Cancer Res.* 33:2977 (1973)). Mice are injected intravenously into the tail vein with approximately 5-10  $\mu$ g of radiolabeled antibody fragment protein. Typical doses of radioactivity are 25-40  $\mu$ Ci of  $^{99m}\text{Tc}$ ,  $^{188}\text{Re}$ , or  $^{111}\text{In}$ , 4  $\mu$ Ci of  $^{88}\text{Y}$ , and 10  $\mu$ Ci of  $^{125}\text{I}$ . The mice are sacrificed at predetermined time periods after injection of the labeled antibody fragments, for example at 4 h and 24 h for  $^{99m}\text{Tc}$ , and at 4, 24, 72, 96 and 168 h for  $^{125}\text{I}$ ,  $^{111}\text{In}$ ,  $^{88}\text{Y}$  and  $^{188}\text{Re}$ -labeled antibodies. The mice are sacrificed and dissected and the amount of activity in the kidney is determined by standard methods. An injection standard is used to correct for radioactive decay. Comparison of the results in the control mice with those in the mice that receive the lysine and/or poly-lysine allows determination of the optimal dosage required to achieve the desired effect on kidney uptake of radioactivity. Determination of the dosage of lysine and/or poly-lysine that can be tolerated before toxic effects are observed can be achieved by physiological examination and histological observation of organs by methods. The optimal dosages of lysine and/or poly-lysine that are determined using the mouse model is used to guide the determination of appropriate dosage

levels in human subjects using a standard dosage escalation regimen. Methods for determining effective dosages of lysine and/or poly-lysine for reducing kidney uptake are further illustrated in the Examples, below.

5 Kits containing RAID and RAIT reagents can advantageously include monomeric and/or polymeric lysine.

The present invention, thus generally described, will be understood more readily by reference to the following examples, which are provided by way of illustration and  
10 are not intended to be limiting of the present invention.

### Examples

#### **General Methods**

##### **Preparation of Radiolabeled Antibody Fragments**

The murine monoclonal anti-carcinoembryonic antigen  
15 (anti-CEA) antibody NP-4 and the second generation antibody anti-CEA MN-14 have been described previously (Sharkey et al., *Cancer* 71:2082 (1993)). The anti-colon-specific antigen-p (CSAp) antibody Mu-9 and the anti-B-cell lymphoma (anti-CD22) antibody LL2 (EPB2) have also  
20 been reported. See Blumenthal et al., *Cancer Immunol. Immunother.* 32:303 (1991) and co-pending U.S. Application Serial No. 08/289576. Antibodies were purified from mouse ascites fluid by standard methods using protein A and ion-exchange chromatography on S- and Q-Sepharose  
25 (Pharmacia, Piscataway, NJ) at 4°C. Purity was ascertained by immunoelectrophoresis, sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) and isoelectric focusing.

All antibody fragments were prepared by standard  
30 methods. F(ab')<sub>2</sub> fragments of the NP-4, Mu-9 and LL2 antibodies were prepared by pepsin digestion, and F(ab)<sub>2</sub> fragments of MN-14 were generated by papain digestion. The fragments were purified by protein A chromatography on Protein A-Sepharose (Pharmacia), using the conditions  
35 recommended by the manufacturer. Fab' fragments of NP-4, LL2 and Mu-9 were generated from the corresponding F(ab')<sub>2</sub> fragments, and the Fab fragment of MN-14 was

generated from the corresponding F(ab)<sub>2</sub> fragments by reduction with cysteine using standard methods.

Fab' fragments NP-4 and LL2 were prepared for <sup>99m</sup>Tc-labeling by following the method described in U.S. Patent 5,061,641. For <sup>188</sup>Re-labeling, Fab' fragments of Mu-9 and LL2 containing free sulfhydryl groups were prepared by reduction with 2-20 μM 2-mercaptoethanol for 10 min at 4°C. The reaction products were purified by gel filtration chromatography, mixed with stannous tartrate in 50 mM PBS, pH 5.3, lyophilized and stored under an inert atmosphere.

For <sup>111</sup>In and <sup>88</sup>Y-labeling, isothiocyanate benzyl-DTPA (SCN-Bz-DTPA) conjugates of the F(ab)<sub>2</sub> and Fab fragments of MN-14, and the F(ab')<sub>2</sub> fragment of LL2 were prepared by adding SCN-Bz-DTPA to the antibody (5.0 mg/ml), previously dialyzed against 100 mM Hepes buffer, pH 8.6, containing 150 mM NaCl, at a 8:1 molar excess of DTPA to MAb. After overnight incubation at room temperature, the antibody conjugates were purified from unreacted SCN-Bz-DTPA by gel filtration chromatography on a 1 x 50 cm column of Sephadex G-50 (Pharmacia).

Technetium-99m was obtained from a <sup>99</sup>Mo/<sup>99m</sup>Tc generator system (Syncor, Fairfield, NJ) as a solution of sodium pertechnetate in 0.9% sodium chloride. Rhenium-188 was obtained from a tungsten-188 (<sup>188</sup>W/<sup>188</sup>Re) generator system (Oak Ridge National Laboratory, Oak Ridge, TN) as a solution in 0.9% sodium chloride. Indium-111 was purchased as <sup>111</sup>InCl<sub>3</sub> in 0.1M HCl from NEN-DuPont (Boston, MA). Yttrium-88 was obtained as <sup>88</sup>YCl<sub>3</sub> in 6 M HCl from NEN-DuPont. Iodine-125 was obtained from NEN-DuPont.

Radioiodination was carried out with <sup>125</sup>I using the iodogen method as previously described. See Fraker et al., *Biochem. Biophys. Res. Comm.* 80:849 (1978). For <sup>99m</sup>Tc- and <sup>188</sup>Re-labeling, the lyophilized antibody fragments prepared as described above were reconstituted with sodium pertechnetate or perrhenate in 0.9 % saline. Labeling with <sup>111</sup>indium and <sup>88</sup>yttrium was carried out by

standard methods. See, for example, "Advanced Methods for Radiolabeling Monoclonal Antibodies with Therapeutic Radionuclides" in Goldenberg, *supra*.

5      **Determination of Reduction of kidney uptake of radioactivity**

Female BALB/c mice, 19 to 22 g of weight, 4 to 5 weeks of age (Charles River Laboratories, Boston, MA) were used as non-tumor-bearing animals. For a human tumor xenograft model, the human colon carcinoma cell  
10      line GW39 (Primus et al. *supra*) was grown subcutaneously in 5- to 6 week-old female athymic mice (Harlan, Madison, WI). Animals were injected intravenously into the tail vein with approximately 5-10  $\mu$ g of antibody fragment protein (i.e., 25-40  $\mu$ Ci of  $^{99m}\text{Tc}$ ,  $^{188}\text{Re}$ , and  $^{111}\text{In}$ , resp.;  
15      4  $\mu$ Ci of  $^{88}\text{Y}$ , and 10  $\mu$ Ci of  $^{125}\text{I}$ , respectively).

The mice were sacrificed after 4 h and 24 h for  $^{99m}\text{Tc}$ -labeled antibodies, and after 4, 24, 72, 96 and 168 h for  $^{125}\text{I}$ ,  $^{111}\text{In}$ ,  $^{88}\text{Y}$  and  $^{188}\text{Re}$ -labeled antibodies. Mice were sacrificed by anesthesia with sodium pentobarbital and  
20      bled by cardiac puncture. After cervical dislocation, the animals were dissected. Radioactivity in the tumors and tissues (liver, spleen, kidney, lung, intestine, blood and bone) was determined by gamma scintillation counting using an injection standard to correct for  
25      physical decay.

For determination of whole-body clearance and organ uptake kinetics in humans, the ROI (region of interest) technique was applied onto whole-body scans obtained at 10 min, 1 h, and 24 h after antibody administration  
30      (Siemens BODYSCAN, Siemens Gammasonics, Erlangen, FRG). Geometric means were calculated, and after correction for radioactive decay, all values were expressed in percent of injected dose by referring to the whole-body counts at 10 min p.i. without previous voiding of the urinary  
35      bladder (by definition 100% of the injected dose).

**Preparation of amino acid solutions**

L-lysine, D-lysine and L-arginine monohydrochloride salts (Sigma, St. Louis, MO) were dissolved in phosphate-



buffered saline (PBS) at a concentration of 160 mg/ml. L-lysine ethyl ester dihydrochloride was dissolved in PBS to yield a concentration of 80 mg/ml. Poly-L-lysine (1-4 kDa and 15-30 kDa) were used as hydrochloride salts at concentration of 25 mg/ml and 10 mg/ml, respectively.

A commercially available amino acid solution (Periamin X™, Pfrimmer -Kabi-Pharmacia, Erlangen, FRG, containing 8.2 g L-lysine/l and 12 g L-arginine/l.), intended for parenteral nutrition of patients was used as an amino acid source in human patients.

**Example 1. Reduction in kidney uptake by lysine and/or poly-lysine**

**Administration of lysine and poly-lysine-containing solutions**

Animals were injected with the lysine and/or poly-lysine solutions intraperitoneally in amounts and at frequencies as shown below. Human patients were infused intravenously over a three-hour period with 1.5 liters of a commercially available amino acid solution starting 15 min before the antibody injection. The data of a total of 77 patients examined with <sup>99m</sup>Tc-labeled anti-CEA Fab' (NP-4: n=19; F023C5: n=58) were taken as controls (infused with the same volume of 0.9 % saline instead of the amino acid solution).

**Example 2. Effect of L-lysine on Kidney Uptake**

**A. In mice**

Typical kidney uptake and organ kinetics of radiolabeled Fab' and F(ab')<sub>2</sub> fragments are shown in Figure 1. <sup>99m</sup>Tc-labeled Fab' fragments showed a rapid renal uptake, reaching a maximum at 2 h after intravenous antibody injection. At this time-point a plateau was reached, lasting approximately until 4-6h p.i., after which excretion of originally retained activity predominated. Peak values of kidney uptake ranged from 65.0 ± 10.9 %ID/g to 120 ± 15% %ID/g, accounting for an absolute uptake in both kidneys of in between 18 and 35 percent of the originally injected activity.

F(ab')<sub>2</sub> - kinetics With Y and In labeled F(ab)<sub>2</sub> there is a continuous uptake up to 24 h p.i., reaching its highest value at about 55% of the injected dose /g for In, and about 43% of the injected dose /g for the Y label, with subsequent wash-out.

Figure 2 shows the dose-effect relationship between L-lysine, administered i.p., and the kidney uptake of <sup>99m</sup>Tc-labeled Fab' fragments of the monoclonal anti-CEA antibody NP-4 in BALB/c mice. L-lysine was injected i.p. in hourly intervals from 30 min before until 3 h after intravenous antibody injections (-30', 1 h, 2 h, 3 h p.i.). Doses below four times 100 µg/g body weight (given in hourly intervals), produced no significant effect could be observed. At doses above this threshold, a strong dose-effect relationship was found. At 4 x 2000 µg/g, kidney uptake was reduced to 19 ± 1% of the untreated control group at 4 h p.i. The maximum tolerated dose (MTD) of L-lysine in mice was reached at 4 x 2500 µg/g (injected i.p. in hourly intervals). This dose was tolerated without any obvious short or long term toxicity (monitored for three months). At higher doses, the mice began to develop fluid in the body cavities (e.g. pleural effusions). No additional effect on kidney uptake was observed in lysine doses above this MTD (see Figure 2).

The effect of uptake reduction of <sup>99m</sup>Tc-Fab' persisted for 24 hours. This effect was obscured somewhat because in the control group 50-70% of the originally retained technetium had been excreted at this time-point, and therefore lysine-induced reduction appeared less profound than at earlier time-points.

In nude mice bearing human colonic xenografts, no significant influence on the tumor uptake or uptake in any other organ than the kidneys was seen by the lysine treatment (see Table 1).

Less frequent L-lysine administration (once 30 min before antibody administration or twice 30 min before and 1 h after antibody injection) was significantly less

effective than the four injections in hourly intervals. For example, a single injection at 30 min. before antibody administration reduced kidney uptake of Tc-Fab' only to 56.4 % of the control amount, and two injections (at 30 min. before and 1 h after antibody) reduced kidney uptake to 44.1 % of the control amount. In comparison, four injections reduced kidney uptake to 15.5 % of control. See Table 2.

L-lysine had comparable effects on  $^{188}\text{Re}$ -labeled Fab' fragments of the anti-CSAp antibody Mu-9. See Figure 3. Lysine treatment reduced kidney uptake to 29 % of the untreated control after 4 h p.i. No effect on the uptake in the tumor or other organs was observed. Table 3 summarizes the dosimetry of  $^{188}\text{Re}$ -Mu-9 Fab' under control and lysine treatment conditions. The kidney dose under lysine-treatment is approximately 30 % of the renal dose in the control group, whereas no effect on the tumor dose could be observed.

To test the effectiveness of L-lysine in reduction of kidney uptake of indium and yttrium-labeled Fab' fragments, a mixture of  $^{111}\text{In}$  and  $^{88}\text{Y}$ -labeled Fab' fragments of the anti-CEA antibody MN-14 were injected into GW39 colon carcinoma bearing nude mice (injected with four times 2000  $\mu\text{g/g}$  L-lysine; the control group were untreated). Figure 4 and Table 4 summarize the results.

Lysine also reduced the kidney uptake of Fab' fragments labeled with isotopes that are not retained significantly by cells (e.g. iodine). Table 5 summarizes the organ kinetics of an  $^{125}\text{I}$ -labeled Fab' fragment of NP-4. Although the kidney uptake of iodine-labeled Fab' was found much lower than with all radiometals, it was still reduced by L-lysine to 38.7 % of the nontreated control at 4 h p.i., which results in a 50 % reduction of the absorbed dose to the kidney, calculated for a  $^{131}\text{I}$ -labeled Fab' fragment.

Figure 6 and Table 6 summarize the reduction of kidney uptake observed with  $\text{F(ab')}_2$  fragments. Uptake

with  $^{111}\text{In}$ -and  $^{88}\text{Y}$ - F(ab')<sub>2</sub>, was reduced to approximately 30 % of control by lysine treatment. As was observed with Fab' fragments, reduction of uptake persisted for several days. See Figure 6.

with  $^{111}\text{In}$ - and  $^{88}\text{Y}$ - F(ab')<sub>2</sub> was reduced to approximately 30 % of control by lysine treatment. As was observed with Fab' fragments, reduction of uptake persisted for several days. See Figure 6.

Table 1

Dose-effect relationship of treatment with L-lysine and poly-L-lysine (1 - 4 kD) in GW39 colonic cancer xenograft bearing nude mice with anti-CEA <sup>125</sup>I-Tc-Fab' NP-4

5

control

L-lysinepoly-L-lys

0.5mg/g lys 2mg/g lys 0.15mg/g poly  
injection i.p. at injection i.p. at i.v. at  
-30', 1,2,3 h-30', 1,2,3 h-30'

=====

4 h p.i.

10

GW39

3.5±0.6 3.2±0.55 0±1.93 0±1.0

liver

2.0±0.3 1.6±0.2 1.8±1.11 5±0.2

spleen

1.3±0.1 1.0±0.1 1.3±0.11 0±0.1

kidney

58.9±9.6 37.1±3.7 17.5±4.330.8±6.0

% of contr.

100.0 63.0 29.752.2

15

lung

3.1±0.2 5.4±1.34 5±1.43 1±1.2

blood

1.7±0.3 1.6±0.2 1.9±0.21 7±0.2

-----

24 h p.i.

20

GW39

1.7±0.2 1.9±0.52 2±0.62 2±0.3

liver

1.0±0.1 0.9±0.2 1.4±0.30 9±0.1

spleen

0.6±0.1 0.5±0.3 0.7±0.30 7±0.1

kidney

26.7±3.6 18.7±3.9 8.0±3.225.3±5.7

% of contr.

100.0 70.0 30.094.7

25

lung

0.3±0.1 0.4±0.20 9±0.50 8±0.6

blood

0.3±0.0 0.5±0.3 0.3±0.10 3±0.0

=====

Table 2

Effect of less frequent administration of L-lysine on the biodistribution of  $^{99m}\text{Tc}$ -Fab' NP-4 in BALB/c mice (uptake values in % ID/g at 4 h p.i.)

5	organ	control	L-lysine (2000 µg/g)	
			injection once at injection twice at injection 4x at	
			-30', -30' and 1h-30', 1,2,3h	
=====				
10	liver	2.5±0.3	4.9±2.4	2.7±0.52.2±0.5
	spleen	2.3±0.2	3.2±1.2	2.0±0.21.4±0.4
	kidney	122.6±20.8	69.1±9.8	54.1±6.019.0±5.7
	% of contr.	100.0	56.4	44.115.5
	lung	3.4±0.2	6.2±3.84.6±1.72.1±0.9	
	blood	3.3±0.4	4.3±1.8	3.0±0.62.4±0.4
=====				

Table 3

Dosimetry of  $^{186}\text{Re}$ -Fab' Mu-9

	control		L-lysine	
	cGy/mCi	T/NT	cGy/mCiT/NTlys/contr.	
5	=====	=====	=====	=====
	GW39	620.3		763.41.23
	liver	611.3	1.01	587.61.300.96
	spleen	306.0	2.03	289.02.640.94
	kidney	7818.8	0.08	3085.20.250.39
10	lung	537.7	1.73	410.41.860.76
	blood	256.4	2.42	203.13.760.79
	bone	120.9	5.13	107.37.110.89
	=====	=====	=====	=====



Table 4

Effect of treatment with L-lysine (four times 2000 µg/g i.p.) on the dosimetry of anti-CEA Fab' MN-14 in GW39 colonic cancer xenograft bearing nude mice. A mixture of  $^{111}\text{In}$  and  $^{89}\text{Y}$ -labeled Bz-DTPA-Fab' was injected. The  $^{89}\text{Y}$ -dosimetry was calculated based on the  $^{89}\text{Y}$  and  $^{111}\text{In}$ -biodistribution separately.

	control		L-lysine	
	cGy/mCi based on $^{111}\text{In}$	cGy/mCi based on $^{89}\text{Y}$	T/NT yttrium/ $^{111}\text{In}$	cGy/mCi based on T/NT yttrium
10	=====			
GW39	5668.8	4953.8	6478.15751.1	
liver	1736.1	1339.9	3.70	2096.81651.93.48
spleen	607.6	626.9	7.90	564.5499.211.52
kidney	34245.3 100%	33057.2 100%	0.15	7849.06231.00.93 22.9%18.8%
15	=====			
lung	501.0	385.6	12.85662.8431.113.3	
blood	751.2	493.6	10.04985.5664.18.66	
intestine	737.1	519.9	9.53768.1560.210.26	
bone	391.2	493.2	10.04508.7588.49.77	
washed bone	187.0	396.7	12.49277.6486.811.81	
20	=====			

Table 5

Effect of L-lysine (4x2mg/g) on the kidney uptake of  $^{125}\text{I}$ -labeled Fab' NP-4 and the dosimetry for a  $^{131}\text{I}$ -labeled Fab'

$^{131}\text{I}$ -Fab' NP-4			
5	organ	control	L-lysine/lys/control
		cgY/mCi	cgY/mCi
10	liver	81.9	77.2 0.94
	spleen	51.8	42.1 0.81
	kidney	229.5	116.60.51
	lung	126.4	120.20.95
	blood	117.7	116.60.99

Table 6

Effectiveness of L-lysine on the kidney uptake and the dosimetry of yttrium-labeled F(ab')<sub>2</sub> fragments of the anti-CD22 antibody LL2

5	organ	%ID/g 4 h p.i. contr.	lys	%ID/g 48 h p.i.dose (cGy/mCi) contr.lyscontr.lys
		=====		
	liver	5.9±0.5	8.8±1.6	4.0±0.24.5±0.54509.85375.0
	spleen	3.1±0.3	3.5±0.7	3.9±0.53.8±0.62989.23031.9
	kidney	22.9±2.8	13.4±0.8	26.2±4.313.0±1.621230.710813.9
10	% control	100.0	58.5	100.049.6100.050.9
	lungs	5.2±0.9	6.9±2.4	1.9±0.31.9±0.21777.82192.1
	blood	13.4±2.4	12.8±4.7	1.5±0.21.4±0.24146.43651.3

**B. In humans**

Five patients undergoing radioimmunodetection studies with <sup>99m</sup>Tc-labeled Fab' fragments of two anti-CEA antibodies were infused over a three-hour period with a commercially available amino acid solution, containing a total of 1.75 g of L-lysine and 3.75 g of L-arginine as basic amino acids. Quantification of organ uptake kinetics showed a decrease of kidney uptake. See Figure 7. This effect was more pronounced at 24 than at 4 h p.i. Whole-body retention showed slightly lower values in the treated patients.

**Example 3. Effect of D-lysine on Kidney Uptake**

D-lysine was tested under the same conditions as L-lysine (four hourly injections i.p.). D-lysine was found to be equally as effective as the L-isomer in lowering kidney uptake.

**Example 4. Effect of polymeric lysine compounds**

To attempt to reduce the necessity of frequent injections of the kidney uptake reducing agent, polymeric substances of higher molecular weight were investigated. The results obtained are summarized in Table 7. Poly-L-lysine with a molecular weight range of 1-4 kDa reduced kidney uptake with a single i.p. injection at significantly lower doses than the monomer. However, the MTD was reached at 300 µg/g, so that the possible maximal absolute uptake reduction was less than with the monomer. The potency of poly-L-lysine increased with increasing molecular weight. L-lysine of molecular weight 15-30 kDa showed 50 % uptake reduction at 1 x 20 µg/g (MTD 20 µg/g).

Table 7

Effect of poly-L-lysine of different molecular weight on the biodistribution of  $^{99m}\text{Tc}$ -Fab' NP-4 at 4 h p.i.

5	organ	poly-L-lysine administered once 30' before antibody	
		control	1-4kD15-30kD
		100 $\mu\text{g/g}$	200 $\mu\text{g/g}$ 300 $\mu\text{g/g}$ 10 $\mu\text{g/g}$ 20 $\mu\text{g/g}$
		=====	=====
	liver	3.4 $\pm$ 0.4	3.0 $\pm$ 0.2 3.0 $\pm$ 0.43.5 $\pm$ 0.87.3 $\pm$ 3.74.6 $\pm$ 0.7
	spleen	2.1 $\pm$ 1.1	3.0 $\pm$ 0.4 2.7 $\pm$ 0.43.5 $\pm$ 0.43.7 $\pm$ 0.43.8 $\pm$ 0.3
10	kidney	127.7 $\pm$ 15.7	95.5 $\pm$ 4.3 80.5 $\pm$ 6.967.9 $\pm$ 7.573.9 $\pm$ 7.255.7 $\pm$ 6.5
	% control	100.0	74.8 63.053.257.843.6
	lungs	7.7 $\pm$ 1.3	5.9 $\pm$ 3.1 3.9 $\pm$ 2.65.6 $\pm$ 1.06.8 $\pm$ 4.37.9 $\pm$ 3.2
	blood	5.1 $\pm$ 0.4	3.8 $\pm$ 0.1 4.4 $\pm$ 0.55.3 $\pm$ 1.44.7 $\pm$ 0.34.7 $\pm$ 0.2
		=====	=====
15		poly-L-lysine administered twice (30' before and 1h after antibody)	
	kidney	73.0 $\pm$ 6.0	43.7 $\pm$ 10.041.6 $\pm$ 8.8
	% control	100.0	59.956.9
		=====	=====

**Example 5. Effect of mixtures of monomeric and polymeric lysine compounds**

To reach maximal effectiveness with as few injections as possible, combinations of lysine and poly-lysine were tested. The results obtained are summarized in Figure 5. Optimal results were found with two injections of a mixture of 2 mg/g lysine and 20  $\mu$ g/g poly-lysine (15-30 kDa) at 30 min. before and 1 h after antibody administration. Despite the fact that both compounds were given close to their individual maximum tolerated dose, no acute or long-term toxicities could be noticed during monitoring for three months after treatment.

**Example 6. Diagnostic Imaging of Lymphoma**

A posterior abdomen scan of a patient with a gastric carcinoma in the antral region and liver metastasis in the left hepatic lobe who underwent RAID with  $^{99m}\text{Tc}$  Fab' fragment of FO23C5 (Sorin Biomedical, Saluggia, Italy) and was infused with Periamin (see above). The kidney image obtained at 4h and 24h p.i. was much less intense than usually observed with fragments and therefore the primary tumor, which was adjacent to the left kidney, was readily visualized.

The invention has been disclosed broadly and illustrated in reference to representative embodiments described above. Those skilled in the art will recognize that various modifications can be made to the present invention without departing from the spirit and scope thereof.

WHAT IS CLAIMED IS:

1. Use of a compound selected from the group consisting of D-lysine, poly-D-lysine, and poly-L-lysine and pharmaceutically acceptable salts and carboxyl derivatives thereof, in a method of radioimmunodiagnosis or immunotherapy, wherein in said method an antibody fragment conjugate or a radiolabeled antibody fragment is injected into said patient, and an effective amount of one or more of said compounds is administered to said patient to reduce kidney uptake of said antibody fragment conjugate or radiolabeled antibody fragment.

2. The use of a compound selected from the group consisting of D-lysine, poly-D-lysine, and poly-L-lysine, and pharmaceutically acceptable salts or carboxyl derivatives thereof, in the preparation of an agent for use in a method of radioimmunodiagnosis or immunotherapy, wherein in said method an antibody fragment conjugate or a radiolabeled antibody fragment is injected into said patient, and an effective amount of said agent is administered to said patient to reduce kidney uptake of said antibody fragment conjugate or radiolabeled antibody fragment.

3. The use according to claim 1 or claim 2, wherein a mixture of at least two of said compounds is administered to said patient.

4. The use according to any one of claims 1 to 3, wherein said compound is parenterally administered to said patient in a physiologically acceptable aqueous solution.

5. The use according to any one of claims 1 to 4, wherein said compound is orally administered to said patient.

6. The use according to any one of claims 1 to 4, wherein said physiologically acceptable aqueous solution is administered to said patient by continuous infusion.

7. The use according to any one of claims 1 to 4, wherein said physiologically acceptable aqueous solution is administered to said patient by means of at least one injection of a bolus of said solution.

5        8. The use according to any one of claims 1 to 7, wherein said antibody fragment conjugate is a radiolabeled conjugate.

9. The use according to any one of claims 1 to 8, wherein the radiolabel is an imaging isotope, and the  
10       procedure is radioimmunodiagnosis.

10. The use according to any one of claims 1 to 7, wherein the conjugate comprises a cytotoxic agent and the procedure is immunotherapy.

11. The use according to any one of claims 1 to 10, wherein D-lysine is administered to said patient.  
15


12. The use according to any one of claims 1 to 10, wherein poly-D-lysine is administered to said patient.

13. The use according to any one of claims 1 to 10, wherein poly-L-lysine is administered to said patient.

20       14. The use according to claim 12 or 13, wherein said poly-D-lysine and said poly-L-lysine each have a molecular weight of 15-30 kDa.



1/7



**FIG. 2**

**4h p.i.**

Legend:  
 ■ Kidney  
 ○ liver  
 ◇ spleen  
 △ lungs  
 ▽ blood

Y-axis: % ID/g

X-axis: L-lysine ug/g x 4

Annotations: >>>toxic

**24h p.i.**


Tc-99m-Fab'

Y-axis: % ID/g

X-axis: L-lysine ug/g x 4

Annotation: n.d.


3/7

**FIG. 3** Re-188-Fab' Mu-9 in GW39 nude mice

4/7


**FIG. 4**

Indium and yttrium-BzDTPA-Fab' MN-14



Effect of frequency of administration


FIG. 5



6/7

**FIG. 6**


Indium and yttrium-BzDTPA-F(ab)2 MN-14



7/7

**FIG. 7**

Whole-body and organ kinetics with Tc-99m-Fab'



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/03308

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 38/02; C07K 14/00

US CL :514/2; 530/300, 350, 324

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/2; 530/300, 350, 324

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, MEDLINE, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ---- Y	WO, A1, 91/04755 (NEORX CORPORATION) 18 April 1991, see entire document.	1-2 --- 3-14
Y	Clinical Experimental Immunology, Volume 86, issued 1991, Batsford et al, "Surface charge distribution is a determinant of antigen deposition in the renal glomerulus: studies employing 'charge-hybrid' molecules", pages 471-477, see entire document.	1-14
Y	American Journal of Pathology, Volume 142, Number 1, issued January 1993, Russo et al, "Poly-L-lysine-gold probe for the detection of anionic sites in normal glomeruli and in idiopathic and experimentally-induced nephrosis", pages 261-271, see entire document.	1-14

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

20 MAY 1996

Date of mailing of the international search report

31 MAY 1996

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No.: (703) 305-3230

Authorized officer

JULIE REEVES

Telephone No.: (703) 308-0196